Full-Time

Associate Director

Global Program Management, Neuroscience TAU

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

Cambridge, MA, USA

Hybrid

Hybrid role; some on-site days at Kendall Square, Cambridge, MA.

Bachelor's, Master's, PhD

Category
Project & Program Management (1)
Required Skills
Risk Management
Marketing

Get referred to Takeda

See people who can refer or advise you

Requirements
  • Bachelor’s Degree science or business-related field
  • Advanced degree in science or business is preferred
  • Minimum of 8-10 years of strong pharmaceutical industry experience and drug development in all phases of development with significant experience within related functions (e.g. Clinical Science, Clinical Operations, Research, Regulatory, CMC, Marketing)
  • Minimum of 5 years program management experience leading complex pharmaceutical projects in a multi-disciplinary, global environment
  • Demonstrated ability to positively influence outcomes, key project decisions, and strategic problem-solving
  • Proven ability to communicate clearly and present key information objectively to all levels of the organization including executive management
  • Substantial experience in intercultural cooperation
  • Modest people management experience and/or proven leadership experience in managing global, matrix teams
Responsibilities
  • Provide global program management and matrixed leadership to global, cross-functional, cross-divisional teams to drive development and deliver results in early to late-phase major development and/or lifecycle management programs (including established/marketed products) to meet Takeda strategic objectives.
  • Translate the cross-divisional, integrated Global Product Team (GPT) strategy into an efficiently executable plan; predicting and planning solutions to achieve program goals and objectives; driving clarity and removing barriers to ensure team success; interfacing with management and influencing decision-making, proactive management and mitigation of development risks, and ensuring appropriate communication and interface with internal governance.
  • Work closely with the Global Program Leader (GPL), as well as other R&D and Commercial functions to ensure that the scientific and commercial strategies are incorporated into the asset strategy and integrated development plan.
  • May lead key initiatives that have cross-functional or cross-divisional impact that are critical to the objectives of the Therapeutic Area Unit (TAU), Center of Operational Performance (CoOP), CMSO and/or global business objectives.
  • Play a key role in ensuring team effectiveness, partnering with GPL and CoOP to administer team health checks to generate insights, plan & execute appropriate follow-up actions.
  • Identifies and drives innovative process improvements with significant organizational impact and manages, as needed, non-project responsibilities, which can include processes and system optimizations.
  • May have direct people management responsibilities.
  • Partners with GPL to coordinate and facilitate GPT or joint Program Team (for partnered Alliance programs) and/or other cross-functional teams to develop and maintain the asset strategy and integrated development plan in conjuction with TAU and commercial strategy, lifecycle management requirements, and evidence generation/publication needs.
  • Proactively identifies resource requirements necessary to progress asset development in alignment with TAU or enterprise business objectives.
  • Drives clarity with GPT and other relevant stakeholders to communicate asset strategic imperatives to ensure appropriate prioritization.
  • Identifies ways to optimize program execution without compromise to patients or compliance.
  • Accountable to maintain the integrated program level plan, ensuring delivery of critical path activities to progress asset development.
  • Ensures asset strategy and integrated development plan are aligned with the GPT, have a patient-centric focus, incorporate innovative approaches that are meaningful to patients, HCPs, regulators & payers, and adhere to the highest standards of operational excellence in drug development and life cycle management.
  • Manages the strategic GPT forum and assigned subteams to ensure progress of asset development. This includes establishing meeting agendas, facilitating effective team discussions, driving to clear and timely team actions and decisions, driving and holding team members accountable for action follow-through.
  • Ensures team effectiveness through team health checks with development and appropriate follow-through on action plans to boost team productivity.
  • Partners with the GPL to provide financial oversight of the program including global, cross-divisional budgets. Includes consolidation, vetting and prioritization of GPT spending to deliver critical path activities.
  • Proactively addresses and removes barriers to program progress, keeping leadership informed of critical considerations (e.g., resources, performance).
  • Proactively identify potential issues or obstacles and achieves resolution or plans contingencies. Follow issues through to resolution ensuring that all key stakeholders are informed of outcomes and program implications.
  • Provides clarity and direction in urgent or unexpected situations. Independently resolves complex issues and competing priorities that may impact achievement of goals, creates mitigation plans and drives to resolution.
  • Manages scheduled and ad-hoc program status reporting, citing progress to program goals/KPIs, proactively identifying risk with planned mitigation(s), and providing rationale for timeline and budget variances.
  • Participate in annual portfolio analyses to communicate program development progress, opportunities, and risks to Senior & Executive Management.
  • Responsible for coordinating preparation efforts for governance engagement to support and drive asset objectives and deliverables.
  • Practically manages key stakeholders and facilitates relevant communications to appropriate cross-regional, cross-functional, cross-divisional and Alliance partners
  • Provides direction and mentors junior colleagues to work strategically and drive results; identifies opportunities for junior PMs to demonstrate their abilities; uses effective coaching techniques to refocus energy and address barriers to success; leads by example
  • May have responsibility for line management of Sr. Manager and/or Associate Director level GPMs as well as contractors within the GPM function.
  • May support Business Development in-licensing activities to ensure appropriate technical assessment, including development costs and timelines, to support the business case of potential in-licensed compounds.
Desired Qualifications
  • Advanced degree in science or business is preferred
  • Therapeutic Area preferable but not required
  • Experience with Microsoft Project Professional, Excel, PowerPoint & Word
  • Fluent in English

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.